カテゴリ： LP Information, 世界, 医療/バイオ

肺がん用MET阻害剤の世界市場2025-2031：サボリチニブ、テポチニブ、その他

■ 英語タイトル：Global MET Inhibitors for Lung Cancer Market Growth 2025-2031
	■ 発行会社/調査会社：LP Information ■ 商品コード：LP22DC5023 ■ 発行日：2025年2月 ■ 調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ■ 産業分野：医薬品 ■ ページ数：105 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後2-3営業日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥527,040	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥790,560	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,054,080	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[肺がん用MET阻害剤の世界市場2025-2031：サボリチニブ、テポチニブ、その他]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

肺がん用MET阻害剤のグローバル市場規模は、2024年のxxx百万ドルから2031年までにxxx百万ドルに増加すると推定されており、2024年～2031年の年平均成長率（CAGR）はxx%を示しています。貿易戦争とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対する貿易戦争の直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
肺がん用MET阻害剤のアジア太平洋市場は、2024年にxxx百万ドルの市場規模が見込まれ、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。肺がん用MET阻害剤の米国市場は、2024年にxxx百万ドルの規模があり、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。肺がん用MET阻害剤のヨーロッパ市場は、2024年にxxx百万ドルの規模が見込まれ、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。肺がん用MET阻害剤の中国市場は、2024年にxxx百万ドルの規模があり、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要な肺がん用MET阻害剤関連企業としては、Pfizer、 Novartis、 Eli Lilly and Company、 Merck KGaA、 AstraZeneca、 Takeda Pharmaceutical、 Daiichi Sankyo、 Kyowa Kirin、 HUTCHMED、 Beyotime Biotechnology、 Haihe Biopharmaなどをカバーしています。売上の面では世界最大の2社が2024年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながら肺がん用MET阻害剤のグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリューチェーン分析などのミクロの詳細にまで及びます。当レポートは読者が貿易戦争およびロシア・ウクライナ戦争中に世界中で肺がん用MET阻害剤市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、肺がん用MET阻害剤のグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2024年で、市場の予測は2024年～2031年までのものです。

*** 市場セグメンテーション ***

この調査では肺がん用MET阻害剤市場を細分化し、種類別 (サボリチニブ、テポチニブ、その他)、用途別 (病院、ドラッグセンター、その他)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：サボリチニブ、テポチニブ、その他

・用途別区分：病院、ドラッグセンター、その他

・地域別区分
アメリカ州（アメリカ、カナダ、メキシコ、ブラジル）
APAC/アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

*** 各章の紹介 ***
第1章：肺がん用MET阻害剤の範囲、調査方法など
第2章：エグゼクティブサマリー、世界の肺がん用MET阻害剤市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2020年～2024年までの推移データ、および2031年までの市場予測
第3章：企業別肺がん用MET阻害剤の販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章：地域別および国別の肺がん用MET阻害剤の販売量と売上（米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど）
第5/6/7/8章：アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章：市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章：製造コスト構造分析
第11章：販売チャンネル、販売業者および顧客
第12章：地域別、国別、種類別、用途別の世界の肺がん用MET阻害剤市場規模予測
第13章：主要企業の包括的な企業プロファイル
第14章：調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：肺がん用MET阻害剤の年間販売量2020-2031、地域別現状・将来分析
・肺がん用MET阻害剤の種類別セグメント：サボリチニブ、テポチニブ、その他
・肺がん用MET阻害剤の種類別販売量：2020-2024年の販売量、売上、市場シェア、販売価格
・肺がん用MET阻害剤の用途別セグメント：病院、ドラッグセンター、その他
・肺がん用MET阻害剤の用途別販売量：2020-2024年の販売量、売上、市場シェア、販売価格

企業別世界の肺がん用MET阻害剤市場
・企業別のグローバル肺がん用MET阻害剤市場データ：2022-2024年の年間販売量、市場シェア
・企業別の肺がん用MET阻害剤の年間売上：2022-2024年の売上、市場シェア
・企業別の肺がん用MET阻害剤販売価格
・主要企業の肺がん用MET阻害剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

肺がん用MET阻害剤の地域別レビュー
・地域別の肺がん用MET阻害剤市場規模2020-2024：年間販売量、売上
・主要国別の肺がん用MET阻害剤市場規模2020-2024：年間販売量、売上
・アメリカ州の肺がん用MET阻害剤販売の成長
・アジア太平洋の肺がん用MET阻害剤販売の成長
・ヨーロッパの肺がん用MET阻害剤販売の成長
・中東・アフリカの肺がん用MET阻害剤販売の成長

アメリカ州市場
・アメリカ州の国別の肺がん用MET阻害剤販売量、売上（2020-2024）
・アメリカ州の肺がん用MET阻害剤の種類別販売量
・アメリカ州の肺がん用MET阻害剤の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋（APAC）市場
・アジア太平洋の国別の肺がん用MET阻害剤販売量、売上（2020-2024）
・アジア太平洋の肺がん用MET阻害剤の種類別販売量
・アジア太平洋の肺がん用MET阻害剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の肺がん用MET阻害剤販売量、売上（2020-2024）
・ヨーロッパの肺がん用MET阻害剤の種類別販売量
・ヨーロッパの肺がん用MET阻害剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の肺がん用MET阻害剤販売量、売上（2020-2024）
・中東・アフリカの肺がん用MET阻害剤の種類別販売量
・中東・アフリカの肺がん用MET阻害剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・肺がん用MET阻害剤の製造コスト構造分析
・肺がん用MET阻害剤の製造プロセス分析
・肺がん用MET阻害剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・肺がん用MET阻害剤の主要なグローバル販売業者
・肺がん用MET阻害剤の主要なグローバル顧客

地域別の肺がん用MET阻害剤市場予測レビュー
・地域別の肺がん用MET阻害剤市場規模予測（2025-2031）
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・肺がん用MET阻害剤の種類別市場規模予測
・肺がん用MET阻害剤の用途別市場規模予測

主要企業分析
Pfizer、 Novartis、 Eli Lilly and Company、 Merck KGaA、 AstraZeneca、 Takeda Pharmaceutical、 Daiichi Sankyo、 Kyowa Kirin、 HUTCHMED、 Beyotime Biotechnology、 Haihe Biopharma
・企業情報
・肺がん用MET阻害剤製品
・肺がん用MET阻害剤販売量、売上、価格、粗利益（2022-2024）
・主要ビジネス概要
・最新動向

調査の結果

The global market for MET Inhibitors for Lung Cancer is estimated to increase from US$ million in 2024 to reach US$ million by 2031, exhibiting a CAGR of % during 2025-2031. Keeping in mind the uncertainties of Trade War and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of trade war on different end use sectors. These insights are included in the report as a major market contributor.
The APAC MET Inhibitors for Lung Cancer market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
The United States MET Inhibitors for Lung Cancer market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
The Europe MET Inhibitors for Lung Cancer market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
The China MET Inhibitors for Lung Cancer market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
Global key MET Inhibitors for Lung Cancer players cover Pfizer, Novartis, Eli Lilly and Company, Merck KGaA and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2024.

[Report Coverage]
This latest report provides a deep insight into the global MET Inhibitors for Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global MET Inhibitors for Lung Cancer market, with both quantitative and qualitative data, to help readers understand how the MET Inhibitors for Lung Cancer market scenario changed across the globe during trade war and Russia-Ukraine War.
The base year considered for analyses is 2024, while the market estimates and forecasts are given from 2025 to 2031. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the MET Inhibitors for Lung Cancer market and forecasts the market size by Type (Savolitinib, Tepotinib and Other), by Application (Hospital, Drug Center and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Savolitinib
Tepotinib
Other
Segmentation by application
Hospital
Drug Center
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Pfizer
Novartis
Eli Lilly and Company
Merck KGaA
AstraZeneca
Takeda Pharmaceutical
Daiichi Sankyo
Kyowa Kirin
HUTCHMED
Beyotime Biotechnology
Haihe Biopharma

[Chapter Introduction]
Chapter 1: Scope of MET Inhibitors for Lung Cancer, Research Methodology, etc.
Chapter 2: Executive Summary, global MET Inhibitors for Lung Cancer market size (sales and revenue) and CAGR, MET Inhibitors for Lung Cancer market size by region, by type, by application, historical data from 2020 to 2025, and forecast to 2031.
Chapter 3: MET Inhibitors for Lung Cancer sales, revenue, average price, global market share, and industry ranking by company, 2020-2024
Chapter 4: Global MET Inhibitors for Lung Cancer sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global MET Inhibitors for Lung Cancer market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, Novartis, Eli Lilly and Company, Merck KGaA, AstraZeneca, Takeda Pharmaceutical, Daiichi Sankyo, Kyowa Kirin and HUTCHMED, etc.
Chapter 14: Research Findings and Conclusion

*** レポート目次（コンテンツ）***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global MET Inhibitors for Lung Cancer Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for MET Inhibitors for Lung Cancer by Geographic Region, 2020, 2025 & 2031
2.1.3 World Current & Future Analysis for MET Inhibitors for Lung Cancer by Country/Region, 2020, 2025 & 2031
2.2 MET Inhibitors for Lung Cancer Segment by Type
2.2.1 Savolitinib
2.2.2 Tepotinib
2.2.3 Other
2.3 MET Inhibitors for Lung Cancer Sales by Type
2.3.1 Global MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2024)
2.3.2 Global MET Inhibitors for Lung Cancer Revenue and Market Share by Type (2020-2024)
2.3.3 Global MET Inhibitors for Lung Cancer Sale Price by Type (2020-2024)
2.4 MET Inhibitors for Lung Cancer Segment by Application
2.4.1 Hospital
2.4.2 Drug Center
2.4.3 Others
2.5 MET Inhibitors for Lung Cancer Sales by Application
2.5.1 Global MET Inhibitors for Lung Cancer Sale Market Share by Application (2020-2024)
2.5.2 Global MET Inhibitors for Lung Cancer Revenue and Market Share by Application (2020-2024)
2.5.3 Global MET Inhibitors for Lung Cancer Sale Price by Application (2020-2024)
3 Global MET Inhibitors for Lung Cancer by Company
3.1 Global MET Inhibitors for Lung Cancer Breakdown Data by Company
3.1.1 Global MET Inhibitors for Lung Cancer Annual Sales by Company (2022-2024)
3.1.2 Global MET Inhibitors for Lung Cancer Sales Market Share by Company (2022-2024)
3.2 Global MET Inhibitors for Lung Cancer Annual Revenue by Company (2022-2024)
3.2.1 Global MET Inhibitors for Lung Cancer Revenue by Company (2022-2024)
3.2.2 Global MET Inhibitors for Lung Cancer Revenue Market Share by Company (2022-2024)
3.3 Global MET Inhibitors for Lung Cancer Sale Price by Company
3.4 Key Manufacturers MET Inhibitors for Lung Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers MET Inhibitors for Lung Cancer Product Location Distribution
3.4.2 Players MET Inhibitors for Lung Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for MET Inhibitors for Lung Cancer by Geographic Region
4.1 World Historic MET Inhibitors for Lung Cancer Market Size by Geographic Region (2020-2024)
4.1.1 Global MET Inhibitors for Lung Cancer Annual Sales by Geographic Region (2020-2024)
4.1.2 Global MET Inhibitors for Lung Cancer Annual Revenue by Geographic Region
4.2 World Historic MET Inhibitors for Lung Cancer Market Size by Country/Region (2020-2024)
4.2.1 Global MET Inhibitors for Lung Cancer Annual Sales by Country/Region (2020-2024)
4.2.2 Global MET Inhibitors for Lung Cancer Annual Revenue by Country/Region
4.3 Americas MET Inhibitors for Lung Cancer Sales Growth
4.4 APAC MET Inhibitors for Lung Cancer Sales Growth
4.5 Europe MET Inhibitors for Lung Cancer Sales Growth
4.6 Middle East & Africa MET Inhibitors for Lung Cancer Sales Growth
5 Americas
5.1 Americas MET Inhibitors for Lung Cancer Sales by Country
5.1.1 Americas MET Inhibitors for Lung Cancer Sales by Country (2020-2024)
5.1.2 Americas MET Inhibitors for Lung Cancer Revenue by Country (2020-2024)
5.2 Americas MET Inhibitors for Lung Cancer Sales by Type
5.3 Americas MET Inhibitors for Lung Cancer Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC MET Inhibitors for Lung Cancer Sales by Region
6.1.1 APAC MET Inhibitors for Lung Cancer Sales by Region (2020-2024)
6.1.2 APAC MET Inhibitors for Lung Cancer Revenue by Region (2020-2024)
6.2 APAC MET Inhibitors for Lung Cancer Sales by Type
6.3 APAC MET Inhibitors for Lung Cancer Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe MET Inhibitors for Lung Cancer by Country
7.1.1 Europe MET Inhibitors for Lung Cancer Sales by Country (2020-2024)
7.1.2 Europe MET Inhibitors for Lung Cancer Revenue by Country (2020-2024)
7.2 Europe MET Inhibitors for Lung Cancer Sales by Type
7.3 Europe MET Inhibitors for Lung Cancer Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa MET Inhibitors for Lung Cancer by Country
8.1.1 Middle East & Africa MET Inhibitors for Lung Cancer Sales by Country (2020-2024)
8.1.2 Middle East & Africa MET Inhibitors for Lung Cancer Revenue by Country (2020-2024)
8.2 Middle East & Africa MET Inhibitors for Lung Cancer Sales by Type
8.3 Middle East & Africa MET Inhibitors for Lung Cancer Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of MET Inhibitors for Lung Cancer
10.3 Manufacturing Process Analysis of MET Inhibitors for Lung Cancer
10.4 Industry Chain Structure of MET Inhibitors for Lung Cancer
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 MET Inhibitors for Lung Cancer Distributors
11.3 MET Inhibitors for Lung Cancer Customer
12 World Forecast Review for MET Inhibitors for Lung Cancer by Geographic Region
12.1 Global MET Inhibitors for Lung Cancer Market Size Forecast by Region
12.1.1 Global MET Inhibitors for Lung Cancer Forecast by Region (2025-2031)
12.1.2 Global MET Inhibitors for Lung Cancer Annual Revenue Forecast by Region (2025-2031)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global MET Inhibitors for Lung Cancer Forecast by Type
12.7 Global MET Inhibitors for Lung Cancer Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer MET Inhibitors for Lung Cancer Product Offered
13.1.3 Pfizer MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis MET Inhibitors for Lung Cancer Product Offered
13.2.3 Novartis MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Information
13.3.2 Eli Lilly and Company MET Inhibitors for Lung Cancer Product Offered
13.3.3 Eli Lilly and Company MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.3.4 Eli Lilly and Company Main Business Overview
13.3.5 Eli Lilly and Company Latest Developments
13.4 Merck KGaA
13.4.1 Merck KGaA Company Information
13.4.2 Merck KGaA MET Inhibitors for Lung Cancer Product Offered
13.4.3 Merck KGaA MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.4.4 Merck KGaA Main Business Overview
13.4.5 Merck KGaA Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca MET Inhibitors for Lung Cancer Product Offered
13.5.3 AstraZeneca MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Takeda Pharmaceutical
13.6.1 Takeda Pharmaceutical Company Information
13.6.2 Takeda Pharmaceutical MET Inhibitors for Lung Cancer Product Offered
13.6.3 Takeda Pharmaceutical MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.6.4 Takeda Pharmaceutical Main Business Overview
13.6.5 Takeda Pharmaceutical Latest Developments
13.7 Daiichi Sankyo
13.7.1 Daiichi Sankyo Company Information
13.7.2 Daiichi Sankyo MET Inhibitors for Lung Cancer Product Offered
13.7.3 Daiichi Sankyo MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.7.4 Daiichi Sankyo Main Business Overview
13.7.5 Daiichi Sankyo Latest Developments
13.8 Kyowa Kirin
13.8.1 Kyowa Kirin Company Information
13.8.2 Kyowa Kirin MET Inhibitors for Lung Cancer Product Offered
13.8.3 Kyowa Kirin MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.8.4 Kyowa Kirin Main Business Overview
13.8.5 Kyowa Kirin Latest Developments
13.9 HUTCHMED
13.9.1 HUTCHMED Company Information
13.9.2 HUTCHMED MET Inhibitors for Lung Cancer Product Offered
13.9.3 HUTCHMED MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.9.4 HUTCHMED Main Business Overview
13.9.5 HUTCHMED Latest Developments
13.10 Beyotime Biotechnology
13.10.1 Beyotime Biotechnology Company Information
13.10.2 Beyotime Biotechnology MET Inhibitors for Lung Cancer Product Offered
13.10.3 Beyotime Biotechnology MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.10.4 Beyotime Biotechnology Main Business Overview
13.10.5 Beyotime Biotechnology Latest Developments
13.11 Haihe Biopharma
13.11.1 Haihe Biopharma Company Information
13.11.2 Haihe Biopharma MET Inhibitors for Lung Cancer Product Offered
13.11.3 Haihe Biopharma MET Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2022-2024)
13.11.4 Haihe Biopharma Main Business Overview
13.11.5 Haihe Biopharma Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. MET Inhibitors for Lung Cancer Annual Sales CAGR by Geographic Region (2020, 2025 & 2031) & ($ millions)
Table 2. MET Inhibitors for Lung Cancer Annual Sales CAGR by Country/Region (2020, 2025 & 2031) & ($ millions)
Table 3. Major Players of Savolitinib
Table 4. Major Players of Tepotinib
Table 5. Major Players of Other
Table 6. Global MET Inhibitors for Lung Cancer Sales by Type (2020-2024) & (K Units)
Table 7. Global MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2024)
Table 8. Global MET Inhibitors for Lung Cancer Revenue by Type (2020-2024) & ($ million)
Table 9. Global MET Inhibitors for Lung Cancer Revenue Market Share by Type (2020-2024)
Table 10. Global MET Inhibitors for Lung Cancer Sale Price by Type (2020-2024) & (US$/Unit)
Table 11. Global MET Inhibitors for Lung Cancer Sales by Application (2020-2024) & (K Units)
Table 12. Global MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2024)
Table 13. Global MET Inhibitors for Lung Cancer Revenue by Application (2020-2024)
Table 14. Global MET Inhibitors for Lung Cancer Revenue Market Share by Application (2020-2024)
Table 15. Global MET Inhibitors for Lung Cancer Sale Price by Application (2020-2024) & (US$/Unit)
Table 16. Global MET Inhibitors for Lung Cancer Sales by Company (2022-2024) & (K Units)
Table 17. Global MET Inhibitors for Lung Cancer Sales Market Share by Company (2022-2024)
Table 18. Global MET Inhibitors for Lung Cancer Revenue by Company (2022-2024) ($ Millions)
Table 19. Global MET Inhibitors for Lung Cancer Revenue Market Share by Company (2022-2024)
Table 20. Global MET Inhibitors for Lung Cancer Sale Price by Company (2022-2024) & (US$/Unit)
Table 21. Key Manufacturers MET Inhibitors for Lung Cancer Producing Area Distribution and Sales Area
Table 22. Players MET Inhibitors for Lung Cancer Products Offered
Table 23. MET Inhibitors for Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global MET Inhibitors for Lung Cancer Sales by Geographic Region (2020-2024) & (K Units)
Table 27. Global MET Inhibitors for Lung Cancer Sales Market Share Geographic Region (2020-2024)
Table 28. Global MET Inhibitors for Lung Cancer Revenue by Geographic Region (2020-2024) & ($ millions)
Table 29. Global MET Inhibitors for Lung Cancer Revenue Market Share by Geographic Region (2020-2024)
Table 30. Global MET Inhibitors for Lung Cancer Sales by Country/Region (2020-2024) & (K Units)
Table 31. Global MET Inhibitors for Lung Cancer Sales Market Share by Country/Region (2020-2024)
Table 32. Global MET Inhibitors for Lung Cancer Revenue by Country/Region (2020-2024) & ($ millions)
Table 33. Global MET Inhibitors for Lung Cancer Revenue Market Share by Country/Region (2020-2024)
Table 34. Americas MET Inhibitors for Lung Cancer Sales by Country (2020-2024) & (K Units)
Table 35. Americas MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2024)
Table 36. Americas MET Inhibitors for Lung Cancer Revenue by Country (2020-2024) & ($ Millions)
Table 37. Americas MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2024)
Table 38. Americas MET Inhibitors for Lung Cancer Sales by Type (2020-2024) & (K Units)
Table 39. Americas MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2024)
Table 40. Americas MET Inhibitors for Lung Cancer Sales by Application (2020-2024) & (K Units)
Table 41. Americas MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2024)
Table 42. APAC MET Inhibitors for Lung Cancer Sales by Region (2020-2024) & (K Units)
Table 43. APAC MET Inhibitors for Lung Cancer Sales Market Share by Region (2020-2024)
Table 44. APAC MET Inhibitors for Lung Cancer Revenue by Region (2020-2024) & ($ Millions)
Table 45. APAC MET Inhibitors for Lung Cancer Revenue Market Share by Region (2020-2024)
Table 46. APAC MET Inhibitors for Lung Cancer Sales by Type (2020-2024) & (K Units)
Table 47. APAC MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2024)
Table 48. APAC MET Inhibitors for Lung Cancer Sales by Application (2020-2024) & (K Units)
Table 49. APAC MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2024)
Table 50. Europe MET Inhibitors for Lung Cancer Sales by Country (2020-2024) & (K Units)
Table 51. Europe MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2024)
Table 52. Europe MET Inhibitors for Lung Cancer Revenue by Country (2020-2024) & ($ Millions)
Table 53. Europe MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2024)
Table 54. Europe MET Inhibitors for Lung Cancer Sales by Type (2020-2024) & (K Units)
Table 55. Europe MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2024)
Table 56. Europe MET Inhibitors for Lung Cancer Sales by Application (2020-2024) & (K Units)
Table 57. Europe MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2024)
Table 58. Middle East & Africa MET Inhibitors for Lung Cancer Sales by Country (2020-2024) & (K Units)
Table 59. Middle East & Africa MET Inhibitors for Lung Cancer Sales Market Share by Country (2020-2024)
Table 60. Middle East & Africa MET Inhibitors for Lung Cancer Revenue by Country (2020-2024) & ($ Millions)
Table 61. Middle East & Africa MET Inhibitors for Lung Cancer Revenue Market Share by Country (2020-2024)
Table 62. Middle East & Africa MET Inhibitors for Lung Cancer Sales by Type (2020-2024) & (K Units)
Table 63. Middle East & Africa MET Inhibitors for Lung Cancer Sales Market Share by Type (2020-2024)
Table 64. Middle East & Africa MET Inhibitors for Lung Cancer Sales by Application (2020-2024) & (K Units)
Table 65. Middle East & Africa MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2024)
Table 66. Key Market Drivers & Growth Opportunities of MET Inhibitors for Lung Cancer
Table 67. Key Market Challenges & Risks of MET Inhibitors for Lung Cancer
Table 68. Key Industry Trends of MET Inhibitors for Lung Cancer
Table 69. MET Inhibitors for Lung Cancer Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. MET Inhibitors for Lung Cancer Distributors List
Table 72. MET Inhibitors for Lung Cancer Customer List
Table 73. Global MET Inhibitors for Lung Cancer Sales Forecast by Region (2025-2031) & (K Units)
Table 74. Global MET Inhibitors for Lung Cancer Sales Market Forecast by Region
Table 75. Global MET Inhibitors for Lung Cancer Revenue Forecast by Region (2025-2031) & ($ millions)
Table 76. Global MET Inhibitors for Lung Cancer Revenue Market Share Forecast by Region (2025-2031)
Table 77. Americas MET Inhibitors for Lung Cancer Sales Forecast by Country (2025-2031) & (K Units)
Table 78. Americas MET Inhibitors for Lung Cancer Revenue Forecast by Country (2025-2031) & ($ millions)
Table 79. APAC MET Inhibitors for Lung Cancer Sales Forecast by Region (2025-2031) & (K Units)
Table 80. APAC MET Inhibitors for Lung Cancer Revenue Forecast by Region (2025-2031) & ($ millions)
Table 81. Europe MET Inhibitors for Lung Cancer Sales Forecast by Country (2025-2031) & (K Units)
Table 82. Europe MET Inhibitors for Lung Cancer Revenue Forecast by Country (2025-2031) & ($ millions)
Table 83. Middle East & Africa MET Inhibitors for Lung Cancer Sales Forecast by Country (2025-2031) & (K Units)
Table 84. Middle East & Africa MET Inhibitors for Lung Cancer Revenue Forecast by Country (2025-2031) & ($ millions)
Table 85. Global MET Inhibitors for Lung Cancer Sales Forecast by Type (2025-2031) & (K Units)
Table 86. Global MET Inhibitors for Lung Cancer Sales Market Share Forecast by Type (2025-2031)
Table 87. Global MET Inhibitors for Lung Cancer Revenue Forecast by Type (2025-2031) & ($ Millions)
Table 88. Global MET Inhibitors for Lung Cancer Revenue Market Share Forecast by Type (2025-2031)
Table 89. Global MET Inhibitors for Lung Cancer Sales Forecast by Application (2025-2031) & (K Units)
Table 90. Global MET Inhibitors for Lung Cancer Sales Market Share Forecast by Application (2025-2031)
Table 91. Global MET Inhibitors for Lung Cancer Revenue Forecast by Application (2025-2031) & ($ Millions)
Table 92. Global MET Inhibitors for Lung Cancer Revenue Market Share Forecast by Application (2025-2031)
Table 93. Pfizer Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer MET Inhibitors for Lung Cancer Product Offered
Table 95. Pfizer MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Novartis Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 99. Novartis MET Inhibitors for Lung Cancer Product Offered
Table 100. Novartis MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 101. Novartis Main Business
Table 102. Novartis Latest Developments
Table 103. Eli Lilly and Company Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 104. Eli Lilly and Company MET Inhibitors for Lung Cancer Product Offered
Table 105. Eli Lilly and Company MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 106. Eli Lilly and Company Main Business
Table 107. Eli Lilly and Company Latest Developments
Table 108. Merck KGaA Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 109. Merck KGaA MET Inhibitors for Lung Cancer Product Offered
Table 110. Merck KGaA MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 111. Merck KGaA Main Business
Table 112. Merck KGaA Latest Developments
Table 113. AstraZeneca Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 114. AstraZeneca MET Inhibitors for Lung Cancer Product Offered
Table 115. AstraZeneca MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 116. AstraZeneca Main Business
Table 117. AstraZeneca Latest Developments
Table 118. Takeda Pharmaceutical Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 119. Takeda Pharmaceutical MET Inhibitors for Lung Cancer Product Offered
Table 120. Takeda Pharmaceutical MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 121. Takeda Pharmaceutical Main Business
Table 122. Takeda Pharmaceutical Latest Developments
Table 123. Daiichi Sankyo Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 124. Daiichi Sankyo MET Inhibitors for Lung Cancer Product Offered
Table 125. Daiichi Sankyo MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 126. Daiichi Sankyo Main Business
Table 127. Daiichi Sankyo Latest Developments
Table 128. Kyowa Kirin Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 129. Kyowa Kirin MET Inhibitors for Lung Cancer Product Offered
Table 130. Kyowa Kirin MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 131. Kyowa Kirin Main Business
Table 132. Kyowa Kirin Latest Developments
Table 133. HUTCHMED Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 134. HUTCHMED MET Inhibitors for Lung Cancer Product Offered
Table 135. HUTCHMED MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 136. HUTCHMED Main Business
Table 137. HUTCHMED Latest Developments
Table 138. Beyotime Biotechnology Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 139. Beyotime Biotechnology MET Inhibitors for Lung Cancer Product Offered
Table 140. Beyotime Biotechnology MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 141. Beyotime Biotechnology Main Business
Table 142. Beyotime Biotechnology Latest Developments
Table 143. Haihe Biopharma Basic Information, MET Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 144. Haihe Biopharma MET Inhibitors for Lung Cancer Product Offered
Table 145. Haihe Biopharma MET Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 146. Haihe Biopharma Main Business
Table 147. Haihe Biopharma Latest Developments
List of Figures
Figure 1. Picture of MET Inhibitors for Lung Cancer
Figure 2. MET Inhibitors for Lung Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global MET Inhibitors for Lung Cancer Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global MET Inhibitors for Lung Cancer Revenue Growth Rate 2020-2031 ($ Millions)
Figure 8. MET Inhibitors for Lung Cancer Sales by Region (2024 & 2031) & ($ millions)
Figure 9. Product Picture of Savolitinib
Figure 10. Product Picture of Tepotinib
Figure 11. Product Picture of Other
Figure 12. Global MET Inhibitors for Lung Cancer Sales Market Share by Type in 2024
Figure 13. Global MET Inhibitors for Lung Cancer Revenue Market Share by Type (2020-2024)
Figure 14. MET Inhibitors for Lung Cancer Consumed in Hospital
Figure 15. Global MET Inhibitors for Lung Cancer Market: Hospital (2020-2024) & (K Units)
Figure 16. MET Inhibitors for Lung Cancer Consumed in Drug Center
Figure 17. Global MET Inhibitors for Lung Cancer Market: Drug Center (2020-2024) & (K Units)
Figure 18. MET Inhibitors for Lung Cancer Consumed in Others
Figure 19. Global MET Inhibitors for Lung Cancer Market: Others (2020-2024) & (K Units)
Figure 20. Global MET Inhibitors for Lung Cancer Sales Market Share by Application (2020-2024)
Figure 21. Global MET Inhibitors for Lung Cancer Revenue Market Share by Application in 2024
Figure 22. MET Inhibitors for Lung Cancer Revenue Market by Company in 2024 ($ Million)
Figure 23. Global MET Inhibitors for Lung Cancer Revenue Market Share by Company in 2024
Figure 24. Global MET Inhibitors for Lung Cancer Sales Market Share by Geographic Region (2020-2024)
Figure 25. Global MET Inhibitors for Lung Cancer Revenue Market Share by Geographic Region in 2024
Figure 26. Global MET Inhibitors for Lung Cancer Sales Market Share by Region (2020-2024)
Figure 27. Global MET Inhibitors for Lung Cancer Revenue Market Share by Country/Region in 2024
Figure 28. Americas MET Inhibitors for Lung Cancer Sales 2020-2024 (K Units)
Figure 29. Americas MET Inhibitors for Lung Cancer Revenue 2020-2024 ($ Millions)
Figure 30. APAC MET Inhibitors for Lung Cancer Sales 2020-2024 (K Units)
Figure 31. APAC MET Inhibitors for Lung Cancer Revenue 2020-2024 ($ Millions)
Figure 32. Europe MET Inhibitors for Lung Cancer Sales 2020-2024 (K Units)
Figure 33. Europe MET Inhibitors for Lung Cancer Revenue 2020-2024 ($ Millions)
Figure 34. Middle East & Africa MET Inhibitors for Lung Cancer Sales 2020-2024 (K Units)
Figure 35. Middle East & Africa MET Inhibitors for Lung Cancer Revenue 2020-2024 ($ Millions)
Figure 36. Americas MET Inhibitors for Lung Cancer Sales Market Share by Country in 2024
Figure 37. Americas MET Inhibitors for Lung Cancer Revenue Market Share by Country in 2024
Figure 38. United States MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 39. Canada MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 40. Mexico MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 41. Brazil MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 42. APAC MET Inhibitors for Lung Cancer Sales Market Share by Region in 2024
Figure 43. APAC MET Inhibitors for Lung Cancer Revenue Market Share by Regions in 2024
Figure 44. China MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 45. Japan MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 46. South Korea MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 47. Southeast Asia MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 48. India MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 49. Australia MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 50. Europe MET Inhibitors for Lung Cancer Sales Market Share by Country in 2024
Figure 51. Europe MET Inhibitors for Lung Cancer Revenue Market Share by Country in 2024
Figure 52. Germany MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 53. France MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 54. UK MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 55. Italy MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 56. Russia MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 57. Middle East & Africa MET Inhibitors for Lung Cancer Sales Market Share by Country in 2024
Figure 58. Middle East & Africa MET Inhibitors for Lung Cancer Revenue Market Share by Country in 2024
Figure 59. Egypt MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 60. South Africa MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 61. Israel MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 62. Turkey MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 63. GCC Country MET Inhibitors for Lung Cancer Revenue Growth 2020-2024 ($ Millions)
Figure 64. Manufacturing Cost Structure Analysis of MET Inhibitors for Lung Cancer in 2024
Figure 65. Manufacturing Process Analysis of MET Inhibitors for Lung Cancer
Figure 66. Industry Chain Structure of MET Inhibitors for Lung Cancer
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles

※参考情報

肺がんは、世界中で最も一般的ながんの一つであり、治療の選択肢が多様化しています。その中でも、MET阻害剤は特定のがん細胞に対する新しい治療法として注目を集めています。MET（メスチニン）受容体は、細胞の成長、増殖、移動に関与する受容体であり、特に肺がんにおいてその異常な活性が癌の進行に関連しています。

MET遺伝子は、細胞の分裂や生存に関与するシグナル伝達経路を制御しています。この遺伝子の変異や過剰発現は、肺がんの発生や進行において重要な役割を果たしており、そのためMET阻害剤は、細胞の増殖を抑制し、死亡を促進することが期待されています。MET阻害剤は、MET受容体を選択的に標的とし、異常なシグナル伝達を阻害することで、がん細胞のの増殖を抑える作用を持ちます。

MET阻害剤の特徴としては、まず選択性があります。これにより、がん細胞に特異的に作用し、正常な細胞への影響を最小限に抑えることが可能です。また、他の治療法と組み合わせて使用することで、より高い効果を示す場合も多いです。例えば、化学療法や免疫療法との併用によって、相乗効果が期待されるのです。

MET阻害剤の種類には数種類があります。代表的なものとして、エクソメチル（capmatinib）、テポリズマブ（tepotinib）などが挙げられます。これらの薬剤は、特にMETの変異や過剰発現がある患者に対して有効性が示されており、臨床試験を通じてその効果と安全性が確認されています。また、これらの薬剤は経口投与が可能であり、患者にとっても治療の選択肢が広がります。

MET阻害剤の用途としては、主にMET異常を持つ進行性非小細胞肺がん（NSCLC）の治療が挙げられます。進行した肺がんの患者に対して、これらの薬剤が有効であることが臨床試験で証明されつつあります。特に、METエキソン14スキッピングを伴う患者には非常に高い効果が期待されており、治療の選択肢として重要視されています。

関連技術としては、バイオマーカーの検出技術が挙げられます。MET異常の有無を確認するためには、遺伝子検査や組織診断が重要です。これにより、MET阻害剤が適応となる患者を正確に特定し、適切な治療を受けることが可能となります。また、次世代シーケンシング（NGS）技術などが進展することで、より迅速にバイオマーカーを検出し、個別化医療の実現に寄与しています。

さらに、MET阻害剤は単独療法だけでなく、他の抗がん剤や免疫療法との併用治療の研究も進められています。相互作用を詳細に理解することで、より効果的な治療戦略が構築されることが期待されています。現在、一部の研究では、MET阻害剤と免疫チェックポイント阻害剤を併用することで、相乗効果を得ることができる可能性も報告されています。

しかし、MET阻害剤には副作用が存在します。一般的な副作用としては、肝機能障害、胃腸症状、皮膚反応などがあります。そのため、治療にあたりっては綿密なモニタリングが必要です。副作用の管理とともに、効果的な治療戦略の構築が求められます。

最近の研究においては、MET阻害剤の耐性メカニズムについても注目が集まっています。がん細胞は、治療に対する耐性を獲得することがあります。耐性のメカニズムを解明し、その克服方法を見出すことは、今後の治療戦略において非常に重要です。さまざまな新規治療法が開発されている中で、耐性株に対する効果が期待される新しいMET阻害剤の開発も進められています。

また、現在進行中の研究により、MET以外のターゲットに対しても効果を持つコンビネーション療法の可能性が探られています。例えば、他の受容体酵素やシグナル伝達経路との相互作用を考慮した新たな治療アプローチが模索されています。これにより、将来的にはMET阻害剤がより多くの患者に対して効果を示すことが期待されます。

最後に、MET阻害剤の研究と開発においては、患者さんのQOL（生活の質）向上が重要な目標です。効果的かつ安全な治療法の確立に向け、臨床研究は今後も進展し続けるでしょう。新たな治療法の登場により、肺がん治療の選択肢が広がり、多くの患者がより良い治療を受けられる未来が期待されます。

このように、MET阻害剤の研究は今なお進行中であり、多くの可能性を秘めています。患者への新たな治療法の提供を目指し、研究者や医療従事者が力を合わせて尽力しています。今後の動向に注目しつつ、更なる発展があり、肺がん治療の可能性が広がることを願うばかりです。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

肺がん用MET阻害剤の世界市場2025-2031：サボリチニブ、テポチニブ、その他

グローバル市場調査会社